Ra Medical Systems
2070 Las Palmas Dr.
Tel: 877-635-1800 or 760-804-1648
35 articles with Ra Medical Systems
Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, today announced that it received a notice from the NYSE indicating that Ra Medical
Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, today reported certain preliminary results for the quarter ended June 30, 2019, as well as a leadership transition.
Ra Medical Systems, Inc. (NYSE: RMED) today announced the launch of Pharos, Optimized, the next generation of Pharos excimer lasers, designed to enhance physician and patient experience with faster treatments for psoriasis, vitiligo, and atopic dermatitis; extended peak performance; and a new ergonomic handpiece for operator comfort and greater treatment site visibility.
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ra Medical Systems, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ra Medical Systems, Inc. of the August 6, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
The study will gather data two years post-treatment in up to 2,500 patients.
RA MEDICAL CLASS ACTION: Rosen, a Globally Recognized Law Firm, Announces the Filing of a Securities Class Action Lawsuit Against Ra Medical Systems, Inc.; Investors with Losses in Excess of $100K are Encouraged to Contact the Firm - RMED
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Ra Medical Systems, Inc. pursuant and/or traceable to the registration statement and prospectus issued in connection with Ra Medical's September 2018 initial public offering.
Ra Medical Systems, Inc. announced that Dr. Mohammad Ansari will present DABRA as a treatment for critical limb ischemia (CLI) during a scientific case review May 21 at the SCAI annual meeting in Las Vegas.
Ra Medical Systems Sues Strata Skin Sciences for False, Misleading, and Disparaging Statements in Connection with Ra Medical’s Initial Public Offering
Ra Medical alleges that the statements breached the non-disparagement provision of a prior settlement agreement to which Strata was expressly bound.
Ra Medical Systems Announces Platinum Partnership with OEIS: Demonstrating Commitment to Deliver High-Quality Care in Office Interventional Suites
Ra Medical Systems was recognized for its shared vision and financial contribution at the OEIS 6th annual national meeting in St. Petersburg, FL.
Ra Medical Systems, Inc. reports financial results for the three months ended March 31, 2019 and provides a business update.
Ra Medical Systems, Inc. announces that it will report first quarter 2019 financial results after market close on Monday, May 13, 2019.
DABRA Excimer Laser Atherectomy to be Presented in Key Events at Charing Cross International Symposium
These events include case and podium presentations and hands-on workshops with Charles Bailey, MD, interventional cardiologist at Heart Endovascular and Rhythm of Texas in San Antonio, USA, and Max Amor, MD, interventional cardiologist at Clinique Louis Pasteur in Nancy, France.
Introduces new integrated commercial strategy to support physician adoption of the DABRA laser system and build long-term customer relationships
New Study Shows DABRA Laser System Achieved 94% Success Rate in Patients with Peripheral Artery Disease
Ra Medical Systems, Inc., announced study results from Athar Ansari, MD, Director of the California Heart & Vascular Clinic, who stated, “DABRA is fundamentally changing the way I practice medicine.” Dr. Ansari’s study demonstrated a 94% success rate treating peripheral artery disease (PAD) by ablating arterial blockages.
New Data Presented at LINC 2019 Demonstrates Acute Success with DABRA Excimer Laser System for the Treatment of Peripheral Artery Disease
Ra Medical Systems, Inc. (NYSE: RMED), today announced a 98% success rate in the results from a 52-patient study using the company’s groundbreaking DABRA System for the treatment of above- and below-the-knee peripheral artery disease (PAD) in a presentation titled, “Acute Results of a 52-Patient Cohort at a Single Center with the DABRA Atherectomy System,” by Ashok Kondur, MD, FACC, FSCAI.
Mr. Fogarty brings over two decades of medical device leadership and commercialization experience to Ra Medical Systems and will oversee all aspects of the Company's commercialization efforts
Ra Medical Systems, Inc. (NYSE: RMED) (the Company), a commercial-stage medical device company leveraging its advanced, minimally-invasive excimer laser-based platform for use in the treatment of vascular and dermatological diseases, today reported its financial results for the three and nine-month period ended September 30, 2018.
Ra Medical Systems, Inc. announced that it will release its financial results for the three-month period ended September 30, 2018 on Tuesday, November 13, 2018 after the market close.
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.